[SCHEDULE 13G/A] Silo Pharma, Inc. SEC Filing
This Schedule 13G/A reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively may beneficially own 838,081 shares of Silo Pharma common stock, representing approximately 9.99% of the outstanding common shares. That reported stake primarily reflects 833,334 shares issuable upon exercise of one warrant and 4,747 shares issuable upon exercise of a second warrant.
The filing shows the Reporting Persons have no sole voting or dispositive power and instead hold shared voting and dispositive power over the 838,081 shares. Several additional warrants are subject to blocker provisions that prevent exercise to the extent that conversion would push ownership above certain thresholds; excluding those blocked amounts, the Reporting Persons could be deemed to beneficially own 2,392,524 shares. The filing includes a certification that the securities are not held to change or influence control of the issuer.
Questo Schedule 13G/A segnala che Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC possono collettivamente essere considerati titolari benefici di 838,081 azioni ordinarie di Silo Pharma, pari a circa il 9.99% delle azioni in circolazione. Tale partecipazione riflette principalmente 833,334 azioni esercitabili mediante l'esercizio di una warrant e 4,747 azioni esercitabili mediante l'esercizio di una seconda warrant.
La dichiarazione indica che le persone riportanti non hanno potere di voto o di disposizione esclusivo e detengono invece poteri di voto e di disposizione condivisi sulle 838,081 azioni. Diverse ulteriori warrant sono soggette a clausole di blocco che impediscono l'esercizio nella misura in cui la conversione farebbe superare determinate soglie di possesso; escludendo tali importi bloccati, le persone riportanti potrebbero essere considerate titolari benefici di 2,392,524 azioni. Il deposito contiene inoltre una certificazione che i titoli non sono detenuti al fine di modificare o influenzare il controllo dell'emittente.
Este Schedule 13G/A informa que Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC pueden, de forma conjunta, ser considerados beneficiarios de 838,081 acciones ordinarias de Silo Pharma, lo que representa aproximadamente el 9.99% de las acciones en circulaci贸n. Esta participaci贸n se debe principalmente a 833,334 acciones ejercitables mediante una warrant y 4,747 acciones ejercitables mediante una segunda warrant.
La presentaci贸n muestra que las Personas Informantes no tienen poder de voto o disposici贸n exclusivo y, en su lugar, poseen poderes de voto y disposici贸n compartidos sobre las 838,081 acciones. Varias warrants adicionales est谩n sujetas a disposiciones de bloqueo que impiden su ejercicio en la medida en que la conversi贸n hiciera que la participaci贸n superase ciertos umbrales; excluyendo esos importes bloqueados, las Personas Informantes podr铆an considerarse beneficiarios de 2,392,524 acciones. La presentaci贸n incluye una certificaci贸n de que los valores no se mantienen con el objetivo de cambiar o influir en el control del emisor.
氤� Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� Mitchell P. Kopin, Daniel B. Asher 氚� Intracoastal Capital LLC電� 瓿惦彊鞙茧 Silo Pharma 氤错喌欤� 838,081欤茧ゼ 靷嫟靸� 氤挫湢頃橁碃 鞛堨潉 靾� 鞛堨溂氅�, 鞚措姅 氚滍枆欤检嫕鞚� 鞎� 9.99%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 欤茧 頃� 臧滌潣 鞗岆煱韸� 頄夓偓搿� 鞚疙暅 833,334欤检檧 霊� 氩堨Ц 鞗岆煱韸� 頄夓偓搿� 鞚疙暅 4,747欤茧ゼ 氚橃榿頃╇媹雼�.
靹滊鞐愲姅 氤搓碃鞚鸽摛鞚� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潉 氤挫湢頃橃 鞎婌潓鞚� 氤挫棳欤茧┌, 雽�鞁� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 於旉皜鞝侅澑 鞐煬 鞗岆煱韸鸽姅 靻岇湢 牍勳湪鞚� 韸轨爼 鞛勱硠臧掛潉 齑堦臣頃橃 氇豁晿霃勲 頄夓偓鞐� 鞝滍暅鞚� 霊愲姅 彀嫧 臁绊暛鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟. 鞚措煬頃� 彀嫧霅� 靾橂焿鞚� 鞝滌櫢頃橂┐ 氤搓碃鞚鸽摛鞚� 2,392,524欤茧ゼ 靷嫟靸� 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲媹霛茧姅 鞚胳霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Ce Schedule 13G/A indique que Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC peuvent, collectivement, 锚tre consid茅r茅s comme d茅tenteurs b茅n茅ficiaires de 838,081 actions ordinaires de Silo Pharma, soit environ 9.99% des actions en circulation. Cette participation refl猫te principalement 833,334 actions susceptibles d'锚tre 茅mises 脿 l'exercice d'un warrant et 4,747 actions susceptibles d'锚tre 茅mises 脿 l'exercice d'un second warrant.
Le d茅p么t montre que les personnes d茅clarantes n'ont aucun pouvoir de vote ou de disposition exclusif et d茅tiennent 脿 la place un pouvoir de vote et de disposition partag茅 sur les 838,081 actions. Plusieurs warrants suppl茅mentaires sont soumises 脿 des clauses de blocage qui emp锚chent l'exercice dans la mesure o霉 la conversion ferait d茅passer certains seuils de d茅tention聽; en excluant ces montants bloqu茅s, les personnes d茅clarantes pourraient 锚tre consid茅r茅es comme b茅n茅ficiaires de 2,392,524 actions. Le d茅p么t inclut une certification selon laquelle les titres ne sont pas d茅tenus dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Dieses Schedule 13G/A berichtet, dass Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC gemeinsam beg眉nstigt Inhaber von 838,081 Aktien der Stammaktien von Silo Pharma sein k枚nnen, was etwa 9.99% der ausstehenden Stammaktien entspricht. Die gemeldete Beteiligung ergibt sich haupts盲chlich aus 833,334 Aktien, die durch die Aus眉bung einer Warrant entstehen, und 4,747 Aktien aus der Aus眉bung einer zweiten Warrant.
Die Einreichung zeigt, dass die meldepflichtigen Personen keine alleinige Stimm- oder Verf眉gungsmacht besitzen und stattdessen gemeinsame Stimm- und Verf眉gungsmacht 眉ber die 838,081 Aktien aus眉ben. Mehrere weitere Warrants unterliegen Sperrklauseln, die eine Aus眉bung verhindern, soweit die Umwandlung das Eigentum 眉ber bestimmte Schwellenwerte hinaus erh枚hen w眉rde; ohne diese gesperrten Best盲nde k枚nnten die meldepflichtigen Personen als wirtschaftliche Inhaber von 2,392,524 Aktien angesehen werden. Die Einreichung enth盲lt zudem eine Bescheinigung, dass die Wertpapiere nicht gehalten werden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
- Disclosure of a material stake: Reporting Persons disclose beneficial ownership of 838,081 shares, equal to 9.99% of the class.
- Warrant-based upside: The position is largely driven by warrants (including 833,334 shares from one warrant), creating clear conversion pathways under permitted conditions.
- Certification of passive intent: The filing includes an explicit certification that the securities are not held to change or influence control.
- No sole voting or dispositive power: Each Reporting Person reports 0 shares of sole voting or dispositive power and only shared power over the reported shares.
- Blocker provisions limit conversion: Significant warrant amounts are excluded from current beneficial ownership because they cannot be exercised to the extent they would increase ownership above 9.99% or 4.99%, capping near-term upside in governance influence.
Insights
TL;DR: Reporting persons hold a near-10% economic position via warrants, but blocker provisions and shared power limit immediate control.
The reported 838,081 share position (about 9.99%) is economically meaningful for a small-cap structure and derives largely from warrant exposure (833,334 shares from one warrant). However, the reporters state 0 shares of sole voting or dispositive power and instead report shared control, which constrains their ability to unilaterally influence governance. Multiple warrants contain explicit blocker provisions that prevent conversion if doing so would exceed 9.99% or 4.99% ownership thresholds; without those blockers the position would nominally rise to 2,392,524 shares. For market impact, this filing signals a material passive economic stake but limited immediate governance influence.
TL;DR: The filing documents material warrant-based exposure but affirms passive intent and structural limits on voting influence.
The certification in the filing explicitly states the holdings were not acquired to change control, consistent with a Schedule 13G filing stance. The Reporting Persons disclose shared voting and dispositive power over 838,081 shares and emphasize several warrants include blocker provisions that restrict exercise to avoid surpassing specified ownership caps. From a governance perspective, the combination of shared power and contractual blocker protections reduces the likelihood of an immediate control contest, while leaving open the possibility of increased economic exposure if blockers are removed or restructured in the future.
Questo Schedule 13G/A segnala che Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC possono collettivamente essere considerati titolari benefici di 838,081 azioni ordinarie di Silo Pharma, pari a circa il 9.99% delle azioni in circolazione. Tale partecipazione riflette principalmente 833,334 azioni esercitabili mediante l'esercizio di una warrant e 4,747 azioni esercitabili mediante l'esercizio di una seconda warrant.
La dichiarazione indica che le persone riportanti non hanno potere di voto o di disposizione esclusivo e detengono invece poteri di voto e di disposizione condivisi sulle 838,081 azioni. Diverse ulteriori warrant sono soggette a clausole di blocco che impediscono l'esercizio nella misura in cui la conversione farebbe superare determinate soglie di possesso; escludendo tali importi bloccati, le persone riportanti potrebbero essere considerate titolari benefici di 2,392,524 azioni. Il deposito contiene inoltre una certificazione che i titoli non sono detenuti al fine di modificare o influenzare il controllo dell'emittente.
Este Schedule 13G/A informa que Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC pueden, de forma conjunta, ser considerados beneficiarios de 838,081 acciones ordinarias de Silo Pharma, lo que representa aproximadamente el 9.99% de las acciones en circulaci贸n. Esta participaci贸n se debe principalmente a 833,334 acciones ejercitables mediante una warrant y 4,747 acciones ejercitables mediante una segunda warrant.
La presentaci贸n muestra que las Personas Informantes no tienen poder de voto o disposici贸n exclusivo y, en su lugar, poseen poderes de voto y disposici贸n compartidos sobre las 838,081 acciones. Varias warrants adicionales est谩n sujetas a disposiciones de bloqueo que impiden su ejercicio en la medida en que la conversi贸n hiciera que la participaci贸n superase ciertos umbrales; excluyendo esos importes bloqueados, las Personas Informantes podr铆an considerarse beneficiarios de 2,392,524 acciones. La presentaci贸n incluye una certificaci贸n de que los valores no se mantienen con el objetivo de cambiar o influir en el control del emisor.
氤� Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� Mitchell P. Kopin, Daniel B. Asher 氚� Intracoastal Capital LLC電� 瓿惦彊鞙茧 Silo Pharma 氤错喌欤� 838,081欤茧ゼ 靷嫟靸� 氤挫湢頃橁碃 鞛堨潉 靾� 鞛堨溂氅�, 鞚措姅 氚滍枆欤检嫕鞚� 鞎� 9.99%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 欤茧 頃� 臧滌潣 鞗岆煱韸� 頄夓偓搿� 鞚疙暅 833,334欤检檧 霊� 氩堨Ц 鞗岆煱韸� 頄夓偓搿� 鞚疙暅 4,747欤茧ゼ 氚橃榿頃╇媹雼�.
靹滊鞐愲姅 氤搓碃鞚鸽摛鞚� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潉 氤挫湢頃橃 鞎婌潓鞚� 氤挫棳欤茧┌, 雽�鞁� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堧嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 於旉皜鞝侅澑 鞐煬 鞗岆煱韸鸽姅 靻岇湢 牍勳湪鞚� 韸轨爼 鞛勱硠臧掛潉 齑堦臣頃橃 氇豁晿霃勲 頄夓偓鞐� 鞝滍暅鞚� 霊愲姅 彀嫧 臁绊暛鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟. 鞚措煬頃� 彀嫧霅� 靾橂焿鞚� 鞝滌櫢頃橂┐ 氤搓碃鞚鸽摛鞚� 2,392,524欤茧ゼ 靷嫟靸� 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲媹霛茧姅 鞚胳霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Ce Schedule 13G/A indique que Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC peuvent, collectivement, 锚tre consid茅r茅s comme d茅tenteurs b茅n茅ficiaires de 838,081 actions ordinaires de Silo Pharma, soit environ 9.99% des actions en circulation. Cette participation refl猫te principalement 833,334 actions susceptibles d'锚tre 茅mises 脿 l'exercice d'un warrant et 4,747 actions susceptibles d'锚tre 茅mises 脿 l'exercice d'un second warrant.
Le d茅p么t montre que les personnes d茅clarantes n'ont aucun pouvoir de vote ou de disposition exclusif et d茅tiennent 脿 la place un pouvoir de vote et de disposition partag茅 sur les 838,081 actions. Plusieurs warrants suppl茅mentaires sont soumises 脿 des clauses de blocage qui emp锚chent l'exercice dans la mesure o霉 la conversion ferait d茅passer certains seuils de d茅tention聽; en excluant ces montants bloqu茅s, les personnes d茅clarantes pourraient 锚tre consid茅r茅es comme b茅n茅ficiaires de 2,392,524 actions. Le d茅p么t inclut une certification selon laquelle les titres ne sont pas d茅tenus dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Dieses Schedule 13G/A berichtet, dass Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC gemeinsam beg眉nstigt Inhaber von 838,081 Aktien der Stammaktien von Silo Pharma sein k枚nnen, was etwa 9.99% der ausstehenden Stammaktien entspricht. Die gemeldete Beteiligung ergibt sich haupts盲chlich aus 833,334 Aktien, die durch die Aus眉bung einer Warrant entstehen, und 4,747 Aktien aus der Aus眉bung einer zweiten Warrant.
Die Einreichung zeigt, dass die meldepflichtigen Personen keine alleinige Stimm- oder Verf眉gungsmacht besitzen und stattdessen gemeinsame Stimm- und Verf眉gungsmacht 眉ber die 838,081 Aktien aus眉ben. Mehrere weitere Warrants unterliegen Sperrklauseln, die eine Aus眉bung verhindern, soweit die Umwandlung das Eigentum 眉ber bestimmte Schwellenwerte hinaus erh枚hen w眉rde; ohne diese gesperrten Best盲nde k枚nnten die meldepflichtigen Personen als wirtschaftliche Inhaber von 2,392,524 Aktien angesehen werden. Die Einreichung enth盲lt zudem eine Bescheinigung, dass die Wertpapiere nicht gehalten werden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many Silo Pharma (SILO) shares do the reporting persons beneficially own?
What portion of the 838,081 shares comes from warrants?
Do the reporting persons have sole voting or dispositive power over these shares?
Are there restrictions that prevent exercise of additional warrants?
How many shares would the Reporting Persons beneficially own without the blocker provisions?
